ArticleBreast cancer research and treatment2016
First International Consensus Conference on lesions of uncertain malignant potential in the breast (B3 lesions).
Article in Breast cancer research and treatment, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
64 citing papers in PubMed, 263 citations in OpenAlex.
- Intraductal papillary carcinoma of breast with invasion: A nomogram and survival from the analysis of the SEER database.Cancer medicine · 2023Trial
- Management of Radial Scars and Complex Sclerosing Lesions of the Breast: To Excise or Not to Excise?World journal of surgery · 2026Article
- Tomosynthesis-Guided Vacuum-Assisted Excision of B3 Breast Lesions: Reducing Overtreatment Without Compromising Safety.European journal of breast health · 2026Article
- Variation in Pathological Appearance Across Repeated Sampling from Probably Benign Breast Lesions.Biomedicines · 2025Article
- Breast Lesions of Uncertain Malignant Potential and Risk of Breast Cancer Development: A Single-Center Experience on 10,531 Consecutive Biopsies.Medicina (Kaunas, Lithuania) · 2025Article
- Approach to Architectural Distortion on Digital Mammography-A Prospective Study from Tertiary Care Cancer Center.Indian journal of surgical oncology · 2025Article
- [Use of imaging methods in the current screening, diagnostics and treatment of breast cancer - Professional guidelines. 5th Breast Cancer Consensus Meeting (2025)].Magyar onkologia · 2025Article
- The role of the Kaiser score system in uncertain malignant potential (B3) breast lesions: a pilot study.Diagnostic and interventional radiology (Ankara, Turkey) · 2025Article
- Malignant upgrade in lesions of uncertain malignant potential in the breast (B3 lesions) - is open excision always necessary?Breast cancer research and treatment · 2025Article
- Stromal lymphocytes are associated with upgrade of B3 breast lesions.Breast cancer research : BCR · 2024Article
- Atypical Ductal Hyperplasia and Lobular In Situ Neoplasm: High-Risk Lesions Challenging Breast Cancer Prevention.Cancers · 2024Article
- Atypia detected during breast screening and subsequent development of cancer: observational analysis of the Sloane atypia prospective cohort in England.BMJ (Clinical research ed.) · 2024Observational
- Long-Term Follow-Up of High-Risk Breast Lesions at Vacuum-Assisted Biopsy without Subsequent Surgical Resection.Breast care (Basel, Switzerland) · 2024Article
- Practical Challenges of DBT-Guided VABB: Harms and Benefits, from Literature to Clinical Experience.Cancers · 2023Article
- Evaluating the use of vacuum-assisted excisions in the management of B3 breast lesions.The British journal of radiology · 2023Article
- Implementation of vacuum-assisted excision as a management option for benign and high-risk breast lesions.The British journal of radiology · 2023Article
- Percutaneous vacuum-assisted excision (VAE) of breast lesions of uncertain malignant potential (B3 lesions): a preliminary single-centre Italian experience.La Radiologia medica · 2023Article
- The effect of delay of excisional biopsy on upstage rate for atypical ductal hyperplasia, flat epithelial atypia, intraductal papilloma, and radial scar.Breast cancer research and treatment · 2022Article
- Hospital costs and cosmetic outcome of benign and high-risk breast lesions managed by vacuum-assisted excision versus surgical excision.The British journal of radiology · 2022Article
- Atypical Ductal Hyperplasia: Risk Factors for Predicting Pathologic Upgrade on Excisional Biopsy.Taehan Yongsang Uihakhoe chi · 2022Article
4 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 12 institutions in 4 countries.
Funding
Abstract
The purpose of this study is to obtain a consensus for the therapy of B3 lesions. The first International Consensus Conference on lesions of uncertain malignant potential in the breast (B3 lesions) including atypical ductal hyperplasia (ADH), flat epithelial atypia (FEA), classical lobular neoplasia (LN), papillary lesions (PL), benign phyllodes tumors (PT), and radial scars (RS) took place in January 2016 in Zurich, Switzerland organized by the International Breast Ultrasound School and the Swiss Minimally Invasive Breast Biopsy group-a subgroup of the Swiss Society of Senology. Consensus recommendations for the management and follow-up surveillance of these B3 lesions were developed and areas of research priorities were identified. The consensus recommendation for FEA, LN, PL, and RS diagnosed on core needle biopsy or vacuum-assisted biopsy (VAB) is to therapeutically excise the lesion seen on imaging by VAB and no longer by open surgery, with follow-up surveillance imaging for 5 years. The consensus recommendation for ADH and PT is, with some exceptions, therapeutic first-line open surgical excision. Minimally invasive management of selected B3 lesions with therapeutic VAB is acceptable as an alternative to first-line surgical excision.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.